<DOC>
	<DOCNO>NCT02192697</DOCNO>
	<brief_summary>Purpose study determine follow patient non-small cell lung cancer ( NSCLC ) harbor EGFR activate mutation . - safety tolerability ASP8273 . - pharmacokinetics ( PK ) ASP8273 . - antitumor activity ASP8273 .</brief_summary>
	<brief_title>An Open Study ASP8273 Patients With Non-Small-Cell Lung Cancer ( NSCLC ) Who Have Epidermal Growth Factor Receptor ( EGFR ) Mutations</brief_title>
	<detailed_description>This study consist Phase I Phase II . The objective Phase I determine follow patient non-small cell lung cancer ( NSCLC ) harbor EGFR activate mutation . - safety tolerability ASP8273 . - maximum tolerate dose ( MTD ) and/or recommend phase II dose ( RP2D ) ASP8273 base dose limit toxicity ( DLT ) profile . - pharmacokinetics ( PK ) ASP8273 . - antitumor activity ASP8273 . The objective Phase II determine follow RP2D ASP8273 patient NSCLC harbor EGFR mutation . - efficacy ASP8273 - safety ASP8273 - PK ASP8273</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis NSCLC . Patients confirm del ex19 , L858R , G719X , L861Q mutation among EGFR activate mutation ( patient study site document abovestated EGFR activate mutation enrol study ) . Life expectancy ≥ 12 week base investigator's/subinvestigator 's judgment . [ Phase I ] Patients previously treat EGFR tyrosinekinase inhibitor ( EGFRTKIs ) * Those expect show therapeutic response exist treatment investigator's/subinvestigator 's opinion . [ Phase II ] Patients confirm progressive disease ( PD ) previous treatment EGFRTKIs* ; receive 2 regimen previous treatment , last regimen enrollment include EGFRTKIs . *Erlotinib , gefitinib , EGFRTKIs clinical investigation ( e.g. , neratinib , afatinib , dacomitinib ) Expression EGFRT790M mutation confirm tumor biopsy primary metastatic lesion confirmation PD follow previous treatment EGFRTKIs enrollment , tumor tissue sample collect archived confirmation PD follow previous treatment EGFRTKIs . At least 1 measurable lesion base Response Evaluation Criteria Solid Tumors ( RECIST ) Version 1.1 . Persistent clinical evidence previous antitumor treatment related toxicity ≥ Grade 2 use Japan Clinical Oncology Group ( JCOG ) Japanese translation National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) version 4.0 ( NCI CTCAE v4.0 JCOG ) ( except alopecia skin toxicity consider irrelevant study enrollment investigator/subinvestigator ) . History concurrent interstitial lung disease Received treatment reversible EGFRTKI ( erlotinib gefitinib ) within 8 day start study treatment . Received previous treatment ( except reversible EGFRTKIs ) intend antitumor effect treatment another investigational drug investigational device within 14 day start study treatment . Previously receive treatment EGFRTKIs ( e.g. , CO1686 , AZD9291 ) inhibit EGFR T790M mutation . It plan subject undergo surgical procedure course study subject still unhealed wound previous surgery Symptomatic central nervous system ( CNS ) lesion .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>tolerability</keyword>
	<keyword>ASP8273</keyword>
	<keyword>Non-small Cell Lung Cancer</keyword>
	<keyword>T790M resistance mutation</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Epidermal Growth Factor Receptor mutation</keyword>
	<keyword>irreversible EGFR inhibitor</keyword>
	<keyword>antitumor activity</keyword>
	<keyword>EGFR</keyword>
</DOC>